Waltham-based Thermo Fisher invests $2 billion to enhance manufacturing in the US 

Thermo Fisher Scientific Inc. (NYSE: TMO) this month announced that it plans to invest an additional $2 billion in the United States over the next four years.

The investments will bolster American innovation, manufacturing and economic competitiveness across the life sciences sector, according to a company press release.

As one of the largest manufacturers of medicines in the world, the Waltham-based company enables biopharma companies to develop and produce their medicines in the United States. Company officials said the forthcoming investment will support a more resilient U.S. healthcare supply chain. 

The COVID pandemic and recent tariffs announced by President Donald Trump have raised concerns among business executives about the U.S. healthcare industry’s dependence on medical products from overseas sources.

Thermo Fisher’s planned $2 billion investment comprises $1.5 billion in capital expenditures to enhance and expand U.S. manufacturing operations and $500 million in research and development spending on high-impact innovation.

“Thermo Fisher’s commitment to U.S. manufacturing reflects our confidence that America will continue to lead the world in science and innovation,” said Marc N. Casper, chairman, president and CEO of Thermo Fisher Scientific. “By expanding our U.S. operations, we ensure that life-saving medicines and therapies will continue to be developed and produced in America for decades to come.”

Thermo Fisher has 64 U.S. manufacturing operations, located in 37 states, making analytical instruments, specialty diagnostics and life sciences solutions, as well as providing contract development and manufacturing services for pharmaceutical innovators.

Since 2017, Thermo Fisher has more than doubled in size, going from $21 billion in revenue and 28,000 U.S. employees to $43 billion in revenue and more than 50,000 U.S. employees today. The company also invests $1 billion annually in R&D in the U.S.